- Trial phase
- Approved
- Time to market
- Already approved and marketed (since December 2015)
- Why 3/10
- Bridion is already FDA-approved and commercially marketed with no pending PDUFA, pivotal readout, or other hard binary catalyst in the next 12 months. It is a small product within Merck's massive diversified portfolio, so even generic erosion will not materially move MRK shares.
Bridion is an approved, mature product facing generic erosion (Lupin launched a generic in July 2026). For MRK investors, this is a non-event, Bridion represents a negligible fraction of Merck's ~$60B+ annual revenue. Watch Merck's broader pipeline (Keytruda, Gardasil) and patent cliffs instead.
Price Chart
Executive Summary
BRIDION (sugammadex) is an FDA-approved injection from Merck & Co., Inc. (NYSE: MRK) that reverses the effects of certain muscle relaxants used during surgery. Approved in December 2015, it is a well-established hospital product with a novel mechanism, it encapsulates and neutralizes rocuronium/vecuronium molecules. The drug faces growing generic competition (Lupin launched a generic in July 2026) and is a very small component of Merck's diversified ~$60B+ revenue base. There are no upcoming binary catalysts for this drug, making it a non-factor for MRK investors.
How It Works
Bridion is an injection that works like a molecular cage. During surgery, patients are given muscle relaxants (rocuronium or vecuronium) to keep them still. Bridion selectively captures and encapsulates those relaxant molecules, reversing their effect so the patient can breathe and move normally again after surgery. It works much faster and more predictably than older reversal drugs like neostigmine.
Trial Status
FDA-approved since December 2015 for reversal of neuromuscular blockade in adults and pediatric patients. Post-marketing studies completed. Generic competition now entering the market.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalysts, Bridion is a mature, approved product with no pending PDUFA dates or pivotal readouts.
- Generic erosion from Lupin's July 2026 generic launch is the key commercial dynamic to watch.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report